Polycythemia Vera - Pipeline Insight, 2020
This report can be delivered to the clients within 24 - 48 Hours
DelveInsight’s, “Polycythemia vera – Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Polycythemia vera pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Polycythemia vera: Overview
Polycythemia vera, or PV, is a rare blood disease in which body makes too many red blood cells. The extra red blood cells make the blood thicker than normal. As a result, blood clots can form more easily. These clots can block blood flow through arteries and veins, which can cause a heart attack or stroke. Thicker blood also doesn't flow as quickly to body as normal blood. Slowed blood flow prevents organs from getting enough oxygen, which can cause serious problems, such as angina.
Symptoms
The signs and symptoms of PV include:
Polycythemia vera (PV) may not cause signs or symptoms for years. The disease often is found during routine blood tests done for other reasons. If the results of the blood tests aren't normal, the doctor may want to do more tests. The doctor will diagnose PV based on signs and symptoms, age and overall health, medical history, a physical exam, and test results of the patients. During the physical exam, the doctor will look for signs of PV. He or she will check for an enlarged spleen, red skin on your face, and bleeding from gums. Once it is confirmed that the patient have polycythemia, the next step is to find out whether they have primary polycythemia (polycythemia vera) or secondary polycythemia.
The medical history and physical exam may confirm which type of polycythemia you have. If not, the patient may have tests that check the level of the hormone erythropoietin (EPO) in blood.
People who have PV have very low levels of EPO. People who have secondary polycythemia usually have normal or high levels of EPO.
Treatment
The goals of treating PV are to control symptoms and reduce the risk of complications, especially heart attack and stroke. To do this, PV treatments reduce the number of red blood cells and the level of hemoglobin (an iron-rich protein) in the blood. This brings the thickness of your blood closer to normal. Blood with normal thickness flows better through the blood vessels. This reduces the chance that blood clots will form and cause a heart attack or stroke. Blood with normal thickness also ensures that your body gets enough oxygen. This can help reduce some of the signs and symptoms of PV, such as headaches, vision problems, and itching.
Polycythemia vera Emerging Drugs Chapters
This segment of the Polycythemia vera report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Polycythemia Vera Emerging Drugs
In non-clinical studies, bomedemstat demonstrated robust in vivo efficacy as a single agent, and in combination with other therapeutics across a range of myeloid malignancy models including the myeloproliferative neoplasms encompassing myelofibrosis, essential thrombocythemia and polycythemia vera. It is currently in phase II stage of development.
Further product details are provided in the report.
Polycythemia vera: Therapeutic Assessment
This segment of the report provides insights about the different Polycythemia vera drugs segregated based on following parameters that define the scope of the report, such as:
Polycythemia vera: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Polycythemia vera therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polycythemia vera drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Polycythemia vera – Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Polycythemia vera pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Polycythemia vera: Overview
Polycythemia vera, or PV, is a rare blood disease in which body makes too many red blood cells. The extra red blood cells make the blood thicker than normal. As a result, blood clots can form more easily. These clots can block blood flow through arteries and veins, which can cause a heart attack or stroke. Thicker blood also doesn't flow as quickly to body as normal blood. Slowed blood flow prevents organs from getting enough oxygen, which can cause serious problems, such as angina.
Symptoms
The signs and symptoms of PV include:
- Headaches, dizziness, and weakness
- Shortness of breath and problems breathing while lying down
- Feelings of pressure or fullness on the left side of the abdomen due to an enlarged spleen (an organ in the abdomen)
- Double or blurred vision and blind spots
- Itching all over (especially after a warm bath), reddened face, and a burning feeling on your skin (especially your hands and feet)
- Bleeding from your gums and heavy bleeding from small cuts
- Unexplained weight loss
- Fatigue (tiredness)
- Excessive sweating
- Very painful swelling in a single joint, usually the big toe (called gouty arthritis)
Polycythemia vera (PV) may not cause signs or symptoms for years. The disease often is found during routine blood tests done for other reasons. If the results of the blood tests aren't normal, the doctor may want to do more tests. The doctor will diagnose PV based on signs and symptoms, age and overall health, medical history, a physical exam, and test results of the patients. During the physical exam, the doctor will look for signs of PV. He or she will check for an enlarged spleen, red skin on your face, and bleeding from gums. Once it is confirmed that the patient have polycythemia, the next step is to find out whether they have primary polycythemia (polycythemia vera) or secondary polycythemia.
The medical history and physical exam may confirm which type of polycythemia you have. If not, the patient may have tests that check the level of the hormone erythropoietin (EPO) in blood.
People who have PV have very low levels of EPO. People who have secondary polycythemia usually have normal or high levels of EPO.
Treatment
The goals of treating PV are to control symptoms and reduce the risk of complications, especially heart attack and stroke. To do this, PV treatments reduce the number of red blood cells and the level of hemoglobin (an iron-rich protein) in the blood. This brings the thickness of your blood closer to normal. Blood with normal thickness flows better through the blood vessels. This reduces the chance that blood clots will form and cause a heart attack or stroke. Blood with normal thickness also ensures that your body gets enough oxygen. This can help reduce some of the signs and symptoms of PV, such as headaches, vision problems, and itching.
Polycythemia vera Emerging Drugs Chapters
This segment of the Polycythemia vera report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Polycythemia Vera Emerging Drugs
- PTG-300: Protagonist Therapeutics
- Bomedemstat: Imago BioSciences
In non-clinical studies, bomedemstat demonstrated robust in vivo efficacy as a single agent, and in combination with other therapeutics across a range of myeloid malignancy models including the myeloproliferative neoplasms encompassing myelofibrosis, essential thrombocythemia and polycythemia vera. It is currently in phase II stage of development.
- Givinostat: Italfarmaco
Further product details are provided in the report.
Polycythemia vera: Therapeutic Assessment
This segment of the report provides insights about the different Polycythemia vera drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Polycythemia vera
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravenous
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Gene therapies
- Small molecule
- Vaccines
- Polymers
- Peptides
- Monoclonal antibodies
- Product Type
Polycythemia vera: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Polycythemia vera therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polycythemia vera drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Polycythemia vera R&D. The therapies under development are focused on novel approaches to treat/improve Polycythemia vera.
- In June 2020, Protagonist Therapeutics announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for PTG-300 for the treatment of polycythemia vera.
- In August 2019, Italfarmaco plans a phase III trial of Givinostat in Polycythaemia vera (PO).
- Polycythemia vera Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Polycythemia vera drugs?
- How many Polycythemia vera drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Polycythemia vera?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Polycythemia vera therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Polycythemia vera and their status?
- What are the key designations that have been granted to the emerging drugs?
- Protagonist Therapeutics
- Imago BioSciences
- Italfarmaco
- Sanofi
- Roche
- Kartos Therapeutics, Inc.
- AOP Orphan Pharmaceuticals AG
- PTG-300
- Bomedemstat
- Givinostat
- Fedratinib
- Idasanutlin
- KRT-232
- Pegylated-Proline-interferon alpha-2b
Introduction
Executive Summary
Polycythemia vera: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Polycythemia vera – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Polycythemia vera companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Polycythemia vera Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
PTG-300: Protagonist Therapeutics
Product Description
Research and Development
Product Development Activities
Bomedemstat: Imago BioSciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
Polycythemia vera Key Companies
Polycythemia vera Key Products
Polycythemia vera- Unmet Needs
Polycythemia vera- Market Drivers and Barriers
Polycythemia vera- Future Perspectives and Conclusion
Polycythemia vera Analyst Views
Polycythemia vera Key Companies
Appendix
Executive Summary
Polycythemia vera: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Polycythemia vera – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Polycythemia vera companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Polycythemia vera Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
PTG-300: Protagonist Therapeutics
Product Description
Research and Development
Product Development Activities
Bomedemstat: Imago BioSciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
Polycythemia vera Key Companies
Polycythemia vera Key Products
Polycythemia vera- Unmet Needs
Polycythemia vera- Market Drivers and Barriers
Polycythemia vera- Future Perspectives and Conclusion
Polycythemia vera Analyst Views
Polycythemia vera Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Polycythemia vera
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Polycythemia vera
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Polycythemia vera
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Polycythemia vera
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
